Predicting therapeutic response in IgG4-related disease based on cluster analysis

Abstract To bring the clinical practice of immunoglobulin (Ig)G4-related disease (IgG4-RD) close to personalized medicine, we classified the patient groups and clarified the therapeutic responses of each group. A total of 147 patients enrolled in our registry were classified into four groups by cluster analysis with the software. The therapeutic responses and prognosis of each group were examined. The cluster analysis classified the subjects into four groups: Cluster 1, patients who presented with prominent hypergammaglobulinemia, elevated levels of serum IgG4, and hypocomplementemia; Cluster 2, patients who presented with eosinophilia, elevated concentrations of serum IgG, IgG4, and IgE, and in whom CRP tended to be positive; Cluster 3, patients with younger onset and serum levels of IgG, IgG4, and IgE and peripheral eosinophil counts lower than the other clusters; and Cluster 4, patients with elder onset and low peripheral eosinophil counts. The amounts of glucocorticoid for maintenance treatment were from 5 to 7 mg/d in all groups, but the amounts were significantly greater in Cluster 1 (patients with hypergammaglobulinemia, elevated levels of serum IgG4, and hypocomplementemia) than in Cluster 4 (elder onset patients, relatively low concentrations of peripheral eosinophils). With regard to the use of immunosuppressants and the relapse rate, there were high frequencies in Cluster 1 and Cluster 3 (younger onset patients who presented with mild elevations of serum IgG and IgG4). On the other hand, Cluster 4 showed a low rate of relapse and often could discontinue steroids. The present results suggest that personalized medicine could be provided in IgG4-RD by classifying patients based on their clinical features.

[1]  H. Sugimoto,et al.  Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis , 2016, Gut.

[2]  T. Himi,et al.  Efficacy of abatacept for IgG4-related disease over 8 months , 2016, Annals of the rheumatic diseases.

[3]  J. Stone,et al.  International Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease , 2015, Arthritis & rheumatology.

[4]  T. Awakawa,et al.  Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years , 2015, Annals of the rheumatic diseases.

[5]  K. Imai,et al.  Everyday clinical practice in IgG4-related dacryoadenitis and/or sialadenitis: Results from the SMART database , 2015, Modern rheumatology.

[6]  M. Nojima,et al.  Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment. , 2015, Rheumatology.

[7]  Y. Shinomura,et al.  Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist , 2014, Nature Reviews Rheumatology.

[8]  K. Okazaki,et al.  Comprehensive Diagnostic Criteria for IgG4-Related Disease , 2014 .

[9]  K. Imai,et al.  Relapse patterns in IgG4-related disease , 2012, Annals of the rheumatic diseases.

[10]  T. Hibi,et al.  Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011 , 2012, Modern rheumatology.

[11]  Hisanori UmeharaKazuichi A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details , 2012 .

[12]  Hiroyuki Yamamoto,et al.  A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease , 2006, Modern rheumatology.

[13]  S Miyano,et al.  Open source clustering software. , 2004, Bioinformatics.